CHCWM – Cancer & Hematology Centers of West Michigan

ST-101 (Sapience)

Description:  A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors

Mechanism of action:  Targets CEBP-beta, which is a transcription factor controlling multiple cellular processes (differentiation, cell survival and metabolism)

Target Patient Population:  Breast (HR+), cutaneous melanoma, glioblastoma, prostate cancer

Study Design:  Drug is administered IV every 3 weeks